A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis

Journal of Thoracic and Cardiovascular Surgery

Volumn 137, Issue 1, 2009, Pages 76-81

  Mykén, Pia S U ^a   Bech Hansen, Odd ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTARALDEHYDE;

ADOLESCENT; ADULT; AGED; AORTA VALVE PROSTHESIS; AORTA VALVE REPLACEMENT; ARTICLE; BIOCOR PORCINE BIOPROSTHESIS; CARPENTIER EDWARDS BIOPROSTHESIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE PROSTHESIS; PRIORITY JOURNAL; REOPERATION; SAINT JUDE HEART VALVE PROSTHESIS; SURVIVAL TIME; SWEDEN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; AORTIC VALVE; BIOPROSTHESIS; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; PROSTHESIS DESIGN; SWINE; TIME FACTORS; YOUNG ADULT;

EID: 58249133279     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.05.068     Document Type: Article

References (22)

1. Bonow R.O., Carabello B.A., Chatterjee K., de Leon Jr. A.A.C., Faxon D.P., Freed M.D., et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48 (2006) e1-e148
2. Jamieson W.R.E., Burr L.H., Miyagishima R.T., Germann E., Macnab J.S., Stanford E., et al. Carpentier-Edwards supra-annular aortic porcine bioprosthesis: clinical performance over 20 years. J Thorac Cardiovasc Surg 130 (2005) 994-1000
3. Yankah C., Schubel J., Buz S., Siniawski H., and Hetzer R. Seventeen-year clinical results of 1,037 Mitroflow pericardial heart valve prostheses in the aortic position. J Heart Valve Dis 14 (2005) 172-180
4. Borger M.A., Ivanov J., Armstrong S., Christie-Hrybinsky D., Feindel C.M., and David T.E. Twenty-year results of the Hancock II bioprosthesis. J Heart Valve Dis 15 (2006) 49-56
5. Mykén P.S., Caidahl K., Larsson S., and Berggren H.E. 10-year experience with the Biocor porcine bioprosthesis in the aortic position. J Heart Valve Dis 3 (1994) 648-656
6. Mykén P.S., Caidahl K., Larsson S., and Berggren H.E. 10-year experience with the Biocor porcine bioprosthesis in the mitral position. J Heart Valve Dis 4 (1995) 63-69
7. Mykén P., Bech-Hanssen O., Phipps B., and Caidahl K. Fifteen years follow up with the St. Jude Medical Biocor porcine bioprosthesis. J Heart Valve Dis 9 (2000) 415-422
8. Mykén P. Seventeen-year experience with the St. Jude Medical Biocor porcine bioprosthesis. J Heart Valve Dis 14 (2005) 486-492
9. Kirali K., Guler M., Tuncer A., Daglar B., Ipek G., Isik O., et al. Fifteen-year clinical experience with the Biocor porcine bioprostheses in the mitral position. Ann Thorac Surg 71 (2001) 811-815
10. Pomerantzeff P.M., Brandao C.M., Albuquerque J.M., Stolf N.A., Grinberg M., and Oliveira S.A. Long-term follow up of the Biocor porcine bioprosthesis in the mitral position. J Heart Valve Dis 15 (2006) 763-767
11. Edmunds Jr. L.H., Clark R.E., Cohn L.H., Grunkemeier G.L., Miller D.C., and Weisel R.D. Guidelines for Reporting Morbidity and Mortality After Cardiac Valvular Operations. Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity of The American Association for Thoracic Surgery and The Society of Thoracic Surgeons. J Thorac Cardiovasc Surg 112 (1996) 708-711
12. Bodnar E., and Blackstone E.H. An "actual" problem: Another issue of apples and oranges. J Heart Valve Dis 14 (2005) 706-708
13. Rahimtoola S.H. The next generation of prosthetic heart valves needs a proven track record of patient outcomes at ≥15 to 20 years. J Am Coll Cardiol 42 (2003) 1720-1721
14. The United Kingdom Heart Valve Registry Report 2003 (2005), United Kingdom Heart Valve Registry, London
15. Lund O., and Bland M. Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement. J Thorac Cardiovasc Surg 132 (2006) 20-26
16. Vesely I. The evolution of bioprosthetic heart valve design and its impact on durability. Cardiovasc Pathol 12 (2003) 277-286
17. Schoen F.J. Pathologic findings in explanted clinical bioprosthetic valves fabricated from photooxidized bovine pericardium. J Heart Valve Dis 7 (1998) 174-179
18. Aupart M.R., Mirza A., Meurisse Y.A., Sirinelli A.L., Neville P.H., and Marchand M.A. Perimount pericardial bioprosthesis for aortic calcified stenosis: 18-year experience with 1,133 patients. J Heart Valve Dis 15 (2006) 768-776
19. Marchand M.A., Aupart M.R., Norton R., Goldsmith I.R., Pelletier L.C., Pellerin M., et al. Fifteen-year experience with the mitral Carpentier-Edwards PERIMOUNT pericardial bioprosthesis. Ann Thorac Surg 71 5 Suppl (2001) S236-S239
20. David T.E., Ivanov J., Armstrong S., Feindel C.M., and Cohen G. Late results of heart valve replacement with the Hancock II bioprosthesis. J Thorac Cardiovasc Surg 121 (2001) 268-277
21. Minami K., Zittermann A., Schulte-Eistrup S., Koertke H., and Körfer R. Mitroflow Synergy prostheses for aortic valve replacement: 19 years experience with 1516 patients. Ann Thorac Surg 80 (2005) 1699-1705
22. Clinical communiqué: 20-year results: Carpentier-Edwards Perimount aortic pericardial bioprosthesis (2003), Edwards Lifesciences, Irvine, CA. http://www.edwards.com/products/heartvalves/perimountaorticcommuniquepdf .htm Accessed October 18, 2007